Phase 2 N=80 Nicotinic Receptors and Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: Neurocognitive Efficacy — 0.6; 2.1 MATRICS Neurocognitive T score — p=0.89
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=60 Randomized Placebo Controlled Study to Determine Safety, Pharmacodynamics and Efficacy of ILV-094 in Atopic Dermatitis
Atopic Dermatitis
Primary: Percentage Change in SCORAD — -18.8; -11.7 percentage change
Phase 2 N=20 Atrasentan Spermatogenesis and Testicular Function
Nephropathy · Diabetes
Primary: Percentage of Subjects With a Sperm Concentration < 15 Million Per mL by Treatment Week 26 — 23.5 percentage of participants
Phase 2 N=16 Clomiphene Citrate for Treatment of Acromegaly
Acromegaly
Primary: IGF-1 Levels — 424 ng/mL — p=< 0.05
Phase 2 N=53 A Controlled Trial of Serotonin Reuptake Inhibitors Added to Stimulant Medication in Youth With Severe Mood Dysregulation
Mood Disorder · Mental Disorder Diagnosed in Childhood · Attention Deficit and Disruptive Behavior Disorder
Primary: Percentage of Participants That "Much Improved" (Score of 2) in, or "Completely Recovered" (Score of 1) From Their Irritability Severity, as Measured With the Clinical…
Phase 2 N=36 Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia · Fatigue · Fever
Primary: Overall Response Rate — 24 Participants
Phase 2 N=28 Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
Colorectal Cancer
Primary: Tumor Response Rate Based on Complete Response (CR)+ Partial Response (PR) + Stable Disease (SD) — 0; 1; 0; 4 Participants
Phase 2 N=51 Efficacy and Safety of LEO 19123 Cream in the Treatment of Psoriasis Vulgaris
Psoriasis Vulgaris
Primary: The Percentage Change in PASI (Psoriasis Area Severity Index) — -24.8; -40.2; -46.8; -29.8 percentage change in PASI — p==0.003
Phase 2 N=253 A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic Keratosis
Seborrheic Keratosis
Primary: Mean of Per Subject Percentages of Target Lesions Judged to be Clear (PWA=0) at Visit 8 — 3.72; 49.5; 57.88 Per-Subject Percent of Lesions Clear
Phase 2 N=50 Diabetes Prevention - Immune Tolerance
Prediabetes · Type 1 Diabetes
Primary: Adverse Events — 2; 2 Serious adverse events
Phase 2 N=71 Efficacy of Re-treatment With Cimzia® in Subject With Chronic Plaque Psoriasis
Psoriasis
Primary: Difference in Psoriasis Activity and Severity Index (PASI) Scores Between Week 12 of the First Treatment in Study C87040 [NCT00245765] and Week 12 of Re-treatment in…
Phase 2 N=68 Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
Acute Myeloid Leukemia · Myelodysplastic Syndromes · Agnogenic Myeloid Metaplasia
Primary: Participant Response Rate — 1; 0; 1; 0 Participants
Phase 2 N=57 Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET
Gastroenteropancreatic Neuroendocrine Tumors
Primary: Disease Control Rate (DCR) After 6 Months — 73.5 percentage of subjects
Phase 2 N=19 Development and Pilot Evaluation of a Web-supported Programme of Constraint Induced Therapy Following Stroke (LifeCIT)
Stroke
Primary: Change in Upper Limb Impairment: Motor Activity Log (MAL) Amount of Use (AOU) — 1.02; 0.06; 0.60; 0.29 units on a scale
Phase 2 N=21 A Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects With Refractory, Moderate or More Severe Aplastic Anemia
Cytopaenia
Primary: Hematological Response at Week 26 — 47.6 Percentage of participants